AACE endocrinology and diabetes

Rare liver damage linked to tirzepatide treatment

Updated

Abstract

Alanine transaminase levels rose to 1562 U/L within 24 hours in a patient following tirzepatide treatment.

  • A 60-year-old woman developed liver injury after starting tirzepatide, despite prior safe use of other similar medications.
  • Liver enzymes significantly increased, indicating hepatocellular injury, while other liver function tests remained normal.
  • Imaging revealed fatty infiltration of the liver, but no other common causes of liver injury were identified.
  • Symptoms of tirzepatide-induced liver injury may include mild abdominal pain and elevated liver enzymes, which can be mistaken for gastrointestinal side effects.
  • Discontinuation of tirzepatide led to normalization of liver enzymes within 24 days.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

The authors have no conflicts of interest to disclose.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free